Startup | August 30, 2024
Bayer awards incubator opportunity to Genvor
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Also received tentative approval for 137 mg
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The grant is designated for the research and development of Pyronaridine
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Subscribe To Our Newsletter & Stay Updated
